TY - JOUR T1 - Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients’ experiences and outcomes JF - CMAJ Open SP - E27 LP - E36 DO - 10.9778/cmajo.20120031 VL - 1 IS - 1 AU - Graeme M. Rocker AU - A. Catherine Simpson AU - Joanne Young BHSc AU - Robert Horton AU - Tasnim Sinuff AU - Jillian Demmons AU - Margaret Donahue MDiv MAHSR AU - Paul Hernandez AU - Darcy Marciniuk Y1 - 2013/01/16 UR - http://www.cmajopen.ca/content/1/1/E27.abstract N2 - Background Dyspnea that is refractory to conventional treatments affects up to 50% of patients with advanced chronic obstructive pulmonary disease (COPD). Although professional societies recommend opioids in this setting, evidence supporting their use over months is limited. We conducted a multicentre mixed-methods study to understand patients’ experiences when opioids are added to optimized conventional treatments for advanced COPD. Methods A total of 44 patients (median age 74, range 51–89 years) agreed to participate in this 6-month study. After baseline assessments, immediate-release morphine sulfate syrup (initially 0.5 mg twice daily) was slowly titrated upward based on weekly assessments of symptoms. We conducted semistructured interviews and collected contemporaneous measures of health-related quality of life, severity of dyspnea, anxiety, depression, global ratings of opioid “helpfulness” and adverse effects before, at 2 months and at 4–6 months after opioids were started. Results Of the 44 patients, 32 (73%) completed the trial; 27 (90%) of 30 patients reported the opioid treatment as very (43%) or somewhat (47%) helpful. Three main themes emerged from the patients’ overall positive experiences: small gains have big impact; realign hopes with reality; and “try it.” Significant improvements were observed in median (interquartile range) scores between baseline and 4–6 months’ assessment for health-related quality of life (Chronic Respiratory Questionnaire: 3.5 [2.8–4.0] v. 4.2 [3.6–4.8]; and Chronic Respiratory Questionnaire–Dyspnea domain: 2.8 [2.3–3.6] v. 3.9 [2.8–4.5]) and decreases in severity of dyspnea (numerical rating scale: 7.0 [5.0–8.0] v. 5.0 [4.0–6.0]). Adverse effects were minimal for most patients. Interpretation Opioids were a helpful and acceptable intervention for refractory dyspnea in patients with advanced COPD. Many of the patients experienced sustained benefits over months, which supports recent recommendations to consider opioids in this setting. Trial registration: ClinicalTrial.gov, no. NCT00982891 ER -